Barclays’s Icosavax, Inc. Common Stock ICVX Stock Holding History

Barclays’s Portfolio ICVX Stock Details ICVX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-37,775	Closed	-$595K	–	5472
2023 Q4	$595K	Sell	37,775 -164,407	-81%	-$1.58M	﹤0.01%	3772
2023 Q3	$1.57M	Buy	202,182 +196,702	+3,589%	+$1.63M	﹤0.01%	2036
2023 Q2	$54.4K	Sell	5,480 -7,611	-58%	-$60.9K	﹤0.01%	3805
2023 Q1	$75.9K	Buy	13,091 +7,071	+117%	+$61.1K	﹤0.01%	4310
2022 Q4	$47.8K	Buy	6,020 +5,026	+506%	+$21.6K	﹤0.01%	4568
2022 Q3	$3K	Sell	994 -10,262	-91%	-$64.2K	﹤0.01%	4605
2022 Q2	$64K	Buy	11,256 +7,274	+183%	+$56.8K	﹤0.01%	3950
2022 Q1	$28K	Buy	+3,982	New	+$62.6K	﹤0.01%	4336

Barclays's ICVX Position: Q1 2024 in Review

Barclays sold out of Icosavax, Inc. Common Stock (ICVX) in Q1 2024, closing a stake of 37,775 shares — an estimated $595K sold.

Barclays first reported a position in ICVX in Q1 2022 and held it in 8 quarters. The position peaked at $1.57M in Q3 2023. 0 funds tracked by Wall St. Rank hold ICVX as of Q1 2024.

Barclays reported no remaining Icosavax, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
Barclays sold 37,775 Icosavax, Inc. Common Stock shares in Q1 2024, an estimated $595K.
Barclays first reported a position in Icosavax, Inc. Common Stock in Q1 2022 and held it in 8 quarters.
Barclays's Icosavax, Inc. Common Stock position peaked at $1.57M in Q3 2023.
0 funds tracked by Wall St. Rank held Icosavax, Inc. Common Stock as of Q1 2024.

Based on Barclays's 13F filing for Q1 2024, filed 15 May 2024.